CN114907446B - 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法 - Google Patents

基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法 Download PDF

Info

Publication number
CN114907446B
CN114907446B CN202210057239.7A CN202210057239A CN114907446B CN 114907446 B CN114907446 B CN 114907446B CN 202210057239 A CN202210057239 A CN 202210057239A CN 114907446 B CN114907446 B CN 114907446B
Authority
CN
China
Prior art keywords
antibody
seq
isolated polypeptide
activatable antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210057239.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114907446A (zh
Inventor
S·J·摩尔
M·T·L·阮
D·R·霍斯特特
O·瓦西尔耶瓦
J·G·萨格特
J·A·特雷特
J·W·韦斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomx Therapeutics Inc
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Priority to CN202210057239.7A priority Critical patent/CN114907446B/zh
Publication of CN114907446A publication Critical patent/CN114907446A/zh
Application granted granted Critical
Publication of CN114907446B publication Critical patent/CN114907446B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
CN202210057239.7A 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法 Active CN114907446B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210057239.7A CN114907446B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562105490P 2015-01-20 2015-01-20
US62/105490 2015-01-20
US201562258015P 2015-11-20 2015-11-20
US62/258015 2015-11-20
US201662278713P 2016-01-14 2016-01-14
US62/278713 2016-01-14
CN202210057239.7A CN114907446B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
PCT/US2016/014132 WO2016118629A1 (en) 2015-01-20 2016-01-20 Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
CN201680016951.5A CN107531758B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680016951.5A Division CN107531758B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法

Publications (2)

Publication Number Publication Date
CN114907446A CN114907446A (zh) 2022-08-16
CN114907446B true CN114907446B (zh) 2024-08-02

Family

ID=55358121

Family Applications (7)

Application Number Title Priority Date Filing Date
CN202210057237.8A Pending CN114716513A (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202210057239.7A Active CN114907446B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN201680016951.5A Active CN107531758B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202210057240.XA Active CN114685661B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202210057236.3A Active CN114478704B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202410943131.7A Pending CN119119209A (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202210057238.2A Active CN114685611B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210057237.8A Pending CN114716513A (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN201680016951.5A Active CN107531758B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202210057240.XA Active CN114685661B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202210057236.3A Active CN114478704B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202410943131.7A Pending CN119119209A (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN202210057238.2A Active CN114685611B (zh) 2015-01-20 2016-01-20 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法

Country Status (20)

Country Link
US (5) US11046759B2 (enExample)
EP (2) EP3247393B1 (enExample)
JP (3) JP6996981B2 (enExample)
KR (1) KR102784383B1 (enExample)
CN (7) CN114716513A (enExample)
AU (2) AU2016209403A1 (enExample)
CA (1) CA2974087A1 (enExample)
DK (1) DK3247393T3 (enExample)
EA (1) EA201791647A1 (enExample)
ES (1) ES2919879T3 (enExample)
HR (1) HRP20220631T8 (enExample)
HU (1) HUE058974T2 (enExample)
IL (2) IL253599B2 (enExample)
MA (1) MA41374A (enExample)
PL (1) PL3247393T3 (enExample)
PT (1) PT3247393T (enExample)
RS (1) RS63276B1 (enExample)
SG (2) SG10201913901QA (enExample)
WO (1) WO2016118629A1 (enExample)
ZA (1) ZA202208160B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754072C (en) 2009-03-02 2019-01-15 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
CN104822704B (zh) * 2012-06-14 2020-02-14 医疗生物科学有限公司 针对分化簇3(cd3)的人源化的抗体
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
IL291329B1 (en) 2013-09-25 2025-09-01 Cytomx Therapeutics Inc Polypeptides that can be determined in matrix metalloproteinases and uses thereof
CN106459153B (zh) 2014-01-31 2021-12-21 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US11400157B2 (en) 2015-05-13 2022-08-02 Chugai Seiyaku Kabushiki Kaisha Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US11448643B2 (en) 2016-04-08 2022-09-20 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
KR102584340B1 (ko) 2016-11-03 2023-10-10 브리스톨-마이어스 스큅 컴퍼니 활성화가능한 항-ctla-4 항체 및 그의 용도
CN110177875B (zh) 2016-11-28 2023-11-28 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
CA3039316A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CN110036034A (zh) 2016-12-09 2019-07-19 西雅图遗传学公司 卷曲螺旋掩蔽的二价抗体
CA3048467A1 (en) * 2016-12-29 2018-07-05 Development Center For Biotechnology Klk6-mediated cns-specific antibody prodrug activation
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
WO2019018828A1 (en) * 2017-07-20 2019-01-24 Cytomx Therapeutics, Inc. METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
US11623965B2 (en) 2017-08-16 2023-04-11 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making
IL321773A (en) 2017-10-14 2025-08-01 Cytomx Therapeutics Inc Activatable antibodies and methods for preparing them
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112020010450A2 (pt) 2017-11-28 2020-11-24 Chugai Seiyaku Kabushiki Kaisha polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
WO2019173771A1 (en) * 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
EP3769309A1 (en) * 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
WO2019213444A1 (en) 2018-05-02 2019-11-07 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
WO2020068920A2 (en) 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
KR20250154552A (ko) 2018-09-27 2025-10-28 실리오 디벨럽먼트, 인크. 마스킹된 사이토카인 폴리펩타이드
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
TW202506736A (zh) 2018-10-11 2025-02-16 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CA3120327A1 (en) * 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
WO2020191306A1 (en) 2019-03-21 2020-09-24 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
IL286846B2 (en) 2019-04-26 2025-06-01 Immunogen Inc Camptothecin derivatives
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
KR20220017430A (ko) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
US20230220105A1 (en) * 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
WO2020251878A1 (en) 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
BR112022001320A2 (pt) * 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
KR102386849B1 (ko) 2019-10-14 2022-04-13 포항공과대학교 산학협력단 면역치료를 위한 환경 반응형 접착성 항체전달체 및 이의 제조방법
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
AU2021240872A1 (en) * 2020-03-23 2022-11-17 Zymeworks Bc Inc. Masked IL12 fusion proteins and methods of use thereof
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
CN115667523A (zh) 2020-04-10 2023-01-31 西托姆克斯治疗公司 可活化细胞因子构建体和相关组合物以及方法
ES3040950T3 (en) 2020-08-11 2025-11-06 Janux Therapeutics Inc Cleavable linker compositions and methods
CA3194956A1 (en) 2020-09-11 2022-03-17 Glympse Bio, Inc. Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
EP4251187A4 (en) * 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
WO2023034825A1 (en) 2021-08-30 2023-03-09 Cytomx Therapeutics, Inc. Method for determining protease activity in a biological sample
CA3233707A1 (en) 2021-10-08 2023-04-13 Alexey Yevgenyevich Berezhnoy Activatable cytokine constructs and combination methods
JP2024537101A (ja) 2021-10-08 2024-10-10 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構成体ならびに関連する組成物及び方法
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
US20230183382A1 (en) * 2021-10-15 2023-06-15 Cytomx Therapeutics, Inc. Activatable polypeptide complex
AU2022367525A1 (en) 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
CA3244052A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag ACTIVABLE IL-18 POLYPEPTIDES
WO2023172654A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Method of protease detection
US20250196099A1 (en) 2022-03-23 2025-06-19 Sony Group Corporation Structure
WO2023183888A1 (en) 2022-03-23 2023-09-28 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
EP4499685A1 (en) 2022-03-25 2025-02-05 CytomX Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
EP4504257A1 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
JP2025511187A (ja) 2022-04-01 2025-04-15 サイトムエックス セラピューティクス，インク． Ｃｄ３結合タンパク質及びその使用方法
KR20250011922A (ko) 2022-05-16 2025-01-22 비온디스 비.브이. 신규한 차폐된 항체
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
EP4565690A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030850A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
AR130076A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
AR130079A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2024216194A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052462A2 (en) * 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014107599A2 (en) * 2013-01-04 2014-07-10 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
AR007087A1 (es) 1996-05-10 1999-10-13 Danisco Una codificacion de fragmento de adn aislado para una enzima que posee actividad de alfa-glucuronidasa, fragmento de adn correspondiente, vectorrecombinante que tiene insertada dicha codificacion de fragmento de adn, celula huesped transformada con dicho vector recombinante, metodo para producir alfa-
AUPO930697A0 (en) 1997-09-19 1997-10-09 Walter And Eliza Hall Institute Of Medical Research, The Catalytic antibodies and a method of producing same
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ATE380865T1 (de) 1998-05-13 2007-12-15 Domantis Ltd Phagen-display-selektionssystem für korrekt gefaltete proteine
WO2001055343A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
EP1328632A2 (en) 2000-08-04 2003-07-23 Eli Lilly And Company C1q-related factor, homologous polypeptides and therapeutic uses thereof
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AU9399501A (en) 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
WO2002038796A2 (en) 2000-11-08 2002-05-16 Beth Israel Deaconess Medical Center, Inc. Methods for determining protease cleavage site motifs
US7105333B2 (en) * 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US20030134298A1 (en) * 2001-07-03 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
US7439319B2 (en) 2001-09-14 2008-10-21 Burnham Institute For Medical Research Selective substrates for matrix metalloproteinases
WO2003038083A1 (en) 2001-10-29 2003-05-08 Bayer Healthcare Ag Regulation of human type i adenylate cyclase
AU2003217415B2 (en) * 2002-02-14 2009-01-08 William J Rutter Chimeric molecules for cleavage in a treated host
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US20080166375A1 (en) * 2003-05-06 2008-07-10 The Government Of The United States Of America, As Rep. By The Secretary Of Health And Human Service Activation of Recombinant Diphtheria Toxin Fusion Proteins by Specific Proteases Highly Expressed on the Surface of Tumor Cells
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US9079936B2 (en) 2003-07-01 2015-07-14 University Of Maryland, Baltimore Derivatives of APF and methods of use
US7947289B2 (en) * 2004-02-09 2011-05-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
JP2008535857A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および処置におけるｃａｃｎａ１ｅ
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
CA2645347A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
TWI412367B (zh) * 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2010088691A2 (en) 2009-02-02 2010-08-05 Washington State University Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica
WO2010091122A1 (en) * 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
AU2010215761B2 (en) * 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
WO2011028698A2 (en) 2009-09-02 2011-03-10 Kansas State University Research Foundation Mri and optical assays for proteases
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US20110214205A1 (en) 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
JP6148979B2 (ja) 2010-05-20 2017-06-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 分解性クロストリジウム毒素
GB201009271D0 (en) 2010-06-02 2010-07-21 Promar As Compositions
PL391627A1 (pl) 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
RU2013110876A (ru) * 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
JP6215194B2 (ja) 2011-05-16 2017-10-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 生体直交型薬物活性化
BR112013033801A2 (pt) * 2011-06-28 2017-12-19 Inhibrx Llc proteína de fusão isolada, e, método para tratar ou aliviar um sintoma de uma doença ou distúrbio inflamatórios
US20130078201A1 (en) 2011-09-28 2013-03-28 Susan Daly Topical sunscreen compositions
AU2013251310B2 (en) 2012-04-27 2018-02-15 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
CA2876904C (en) 2012-06-22 2019-12-03 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
EP2988786A4 (en) * 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE
EP3003370B1 (en) 2013-05-28 2020-01-22 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
EP3003387A1 (en) * 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions and methods for conjugating activatable antibodies
IL291329B1 (en) 2013-09-25 2025-09-01 Cytomx Therapeutics Inc Polypeptides that can be determined in matrix metalloproteinases and uses thereof
CN106459153B (zh) 2014-01-31 2021-12-21 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
AU2016257929B2 (en) * 2015-05-04 2022-10-20 Cytomx Therapeutics, Inc Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
TWI787796B (zh) * 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
US10822419B2 (en) 2015-06-26 2020-11-03 University Of Southern California Masking chimeric antigen receptor T cells for tumor-specific activation
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
KR102584340B1 (ko) 2016-11-03 2023-10-10 브리스톨-마이어스 스큅 컴퍼니 활성화가능한 항-ctla-4 항체 및 그의 용도
AU2018231127A1 (en) 2017-03-09 2019-09-19 Cytomx Therapeutics, Inc. CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
US20200116740A1 (en) 2018-10-11 2020-04-16 Northwestern University Discovery and validation of an early post-transplant biomarker predictive of chronic kidney disease in liver transplant recipients
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052462A2 (en) * 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014107599A2 (en) * 2013-01-04 2014-07-10 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface";Jeannette等;《Cancer Immunol Immunother》;第55卷;第15980-1600页 *
Jeannette等."Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface".《Cancer Immunol Immunother》.2006,第55卷第15980-1600页. *

Also Published As

Publication number Publication date
US20210355208A1 (en) 2021-11-18
HRP20220631T8 (hr) 2022-07-08
MA41374A (fr) 2017-11-28
HK1247131A1 (en) 2018-09-21
BR112017015468A2 (pt) 2018-06-05
JP2022046569A (ja) 2022-03-23
US11472875B1 (en) 2022-10-18
NZ772090A (en) 2024-07-05
EA201791647A1 (ru) 2018-04-30
NZ772089A (en) 2024-07-05
CN107531758A (zh) 2018-01-02
IL253599A0 (en) 2017-09-28
US20220380453A9 (en) 2022-12-01
CN114685661A (zh) 2022-07-01
CN114685661B (zh) 2025-01-07
US11548944B2 (en) 2023-01-10
CN114685611B (zh) 2025-01-07
IL253599B2 (en) 2023-07-01
ZA202208160B (en) 2024-11-27
IL253599B1 (en) 2023-03-01
EP4079323A1 (en) 2022-10-26
US20160289324A1 (en) 2016-10-06
KR102784383B1 (ko) 2025-03-24
IL300408B1 (en) 2025-07-01
CN107531758B (zh) 2022-02-11
HRP20220631T1 (hr) 2022-06-24
CN114478704B (zh) 2024-07-26
CN114907446A (zh) 2022-08-16
RS63276B1 (sr) 2022-06-30
JP2018504925A (ja) 2018-02-22
AU2021257963A1 (en) 2021-11-25
HUE058974T2 (hu) 2022-10-28
CN119119209A (zh) 2024-12-13
CN114685611A (zh) 2022-07-01
SG10201913901QA (en) 2020-03-30
US12459999B2 (en) 2025-11-04
US20210347886A1 (en) 2021-11-11
IL300408A (en) 2023-04-01
PT3247393T (pt) 2022-07-01
US11046759B2 (en) 2021-06-29
JP6996981B2 (ja) 2022-03-03
US11548943B2 (en) 2023-01-10
CN114478704A (zh) 2022-05-13
EP3247393B1 (en) 2022-03-09
SG11201705901PA (en) 2017-08-30
JP2024170436A (ja) 2024-12-10
NZ733811A (en) 2024-07-05
KR20170108052A (ko) 2017-09-26
JP7540990B2 (ja) 2024-08-27
US20230021301A9 (en) 2023-01-19
PL3247393T3 (pl) 2022-06-27
ES2919879T3 (es) 2022-07-28
US20190241652A9 (en) 2019-08-08
US20230212283A1 (en) 2023-07-06
AU2016209403A1 (en) 2017-08-03
DK3247393T3 (da) 2022-05-23
CA2974087A1 (en) 2016-07-28
NZ772087A (en) 2024-07-05
WO2016118629A1 (en) 2016-07-28
EP3247393A1 (en) 2017-11-29
CN114716513A (zh) 2022-07-08
IL300408B2 (en) 2025-11-01
AU2021257963B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
JP7540990B2 (ja) マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法
JP7781254B2 (ja) マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
JP2016538240A (ja) マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
HK40083039A (en) Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
HK1247131B (en) Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
BR112017015468B1 (pt) Polipeptídeos isolados, composição farmacêutica compreendendo-os, uso terapêutico destes, molécula de ácido nucleico isolada, vetor, método para produzir um polipeptídeo isolado e método para fabricar um anticorpo ativável que, em um estado ativado, se liga a um alvo
BR122022003994B1 (pt) Polipeptídeos isolados, composição farmacêutica compreendendo os mesmos, uso terapêutico dos mesmos, molécula de ácido nucleico isolada, vetor, bem como métodos de produzir um polipeptídeo isolado e de fabricar um anticorpo ativável que, em um estado ativado, se liga a um alvo
EA042544B1 (ru) Расщепляемые матриксными металлопротеиназами и расщепляемые сериновыми протеиназами вещества и способы их использования

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant